{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:30:14Z","timestamp":1785544214550,"version":"3.56.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurodevelop Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>Hundreds of rare genetic variants associated with autism or intellectual disability have been identified, and many impact genes known to have a primary epigenetic\/chromatin regulatory function. The objective of this study was to examine and compare behavioural profiles and longitudinal psychotropic treatment patterns in children with epigenetic\/chromatin variants, other rare variants impacting neurodevelopment, or no known genetic condition.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Using electronic medical records from a pediatric psychopharmacology program for children with autism or intellectual disability, we compared clinical characteristics, longitudinal psychotropic medication profiles and side effects between those with and without a rare genetic variant, and by variant subtype [epigenetic\/chromatin regulation or other variant].<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 331 children attended 2724 unique medical visits between 2019 and 2022, with a mean of 8 follow-up visits over 3.4\u00a0years. Nine children (3%) had variants in epigenetic\/chromatin regulatory genes (EC), twenty-three children (7%) had other rare genetic variants (OTH), and the rest had no reported variant (NR, <jats:italic>n<\/jats:italic>\u2009=\u2009299, 90%). Those with a rare genetic variant (EC or OTH) were more likely to have an intellectual disability and had a greater number of co-occurring physical health conditions (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Overall, 66% of psychotropic medications were continued for\u2009\u2265\u20093 visits, while 26% were discontinued. Rates of psychotropic polypharmacy, medication patterns, behavioural challenges, and co-occurring developmental diagnoses were similar between genetic groups. Analyses uncorrected for multiple comparisons suggested those with genetic variants were more likely to experience drowsiness\/sedation as a side effect (EC 33%, OTH 35%, NR 16%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05); weight gain as a side effect was also higher in the epigenetic\/chromatin group (EC 50% vs OTH 11%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Genetic classification of neurodevelopmental disorders (NDDs) may help anticipate treatment tolerability; additional prescribing considerations may be needed for those with rare variants. Current psychotropic prescribing practices do not differ across rare genetic NDD subgroups.\n<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s11689-025-09605-9","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T12:49:56Z","timestamp":1745498996000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Psychopharmacology in children with genetic disorders of epigenetic and chromatin regulation"],"prefix":"10.1186","volume":"17","author":[{"given":"Sophia","family":"Lenz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajilan","family":"Sivaloganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Cytrynbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesiqua","family":"Rapley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Canning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Baribeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"9605_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s40474-016-0085-7","volume":"3","author":"K McKenzie","year":"2016","unstructured":"McKenzie K, Milton M, Smith G, Ouellette-Kuntz H. Systematic review of the prevalence and incidence of intellectual disabilities: current trends and issues. Curr Dev Disord Rep. 2016;3:104\u201315.","journal-title":"Curr Dev Disord Rep"},{"issue":"5","key":"9605_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/aur.2696","volume":"15","author":"J Zeidan","year":"2022","unstructured":"Zeidan J, Fombonne E, Scorah J, Ibrahim A, Durkin MS, Saxena S, et al. Global prevalence of autism: a systematic review update. Autism Res. 2022;15(5):778\u201390.","journal-title":"Autism Res"},{"issue":"2","key":"9605_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/13668250.2011.572548","volume":"36","author":"SL Einfeld","year":"2011","unstructured":"Einfeld SL, Ellis LA, Emerson E. Comorbidity of intellectual disability and mental disorder in children and adolescents: A systematic review. J Intellect Dev Disabil. 2011;36(2):137\u201343.","journal-title":"J Intellect Dev Disabil"},{"issue":"10","key":"9605_CR4","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S2215-0366(19)30289-5","volume":"6","author":"MC Lai","year":"2019","unstructured":"Lai MC, Kassee C, Besney R, Bonato S, Hull L, Mandy W, et al. Prevalence of co-occurring mental health diagnoses in the autism population: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(10):819\u201329.","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"9605_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.27415","volume":"6","author":"MC Lai","year":"2023","unstructured":"Lai MC, Saunders NR, Huang A, Artani A, Wilton AS, Zaheer J, et al. Self-harm events and suicide deaths among autistic individuals in Ontario, Canada. JAMA Netw Open. 2023;6(8): e2327415.","journal-title":"JAMA Netw Open"},{"key":"9605_CR6","doi-asserted-by":"publisher","unstructured":"Gohari D, Schiltz H, Lord C. A longitudinal study of aggression in people with autism and other neurodevelopmental disabilities. J Autism Dev Disord. 2024. https:\/\/doi.org\/10.1007\/s10803-024-06559-0. Online ahead of print.","DOI":"10.1007\/s10803-024-06559-0"},{"issue":"2","key":"9605_CR7","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.ridd.2012.10.004","volume":"34","author":"L Davies","year":"2013","unstructured":"Davies L, Oliver C. The age related prevalence of aggression and self-injury in persons with an intellectual disability: a review. Res Dev Disabil. 2013;34(2):764\u201375.","journal-title":"Res Dev Disabil"},{"issue":"5","key":"9605_CR8","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1542\/peds.2012-3774","volume":"132","author":"D Spencer","year":"2013","unstructured":"Spencer D, Marshall J, Post B, Kulakodlu M, Newschaffer C, Dennen T, et al. Psychotropic medication use and polypharmacy in children with autism spectrum disorders. Pediatrics. 2013;132(5):833\u201340.","journal-title":"Pediatrics"},{"key":"9605_CR9","doi-asserted-by":"crossref","unstructured":"Biswas AB, Casey P. Neurodevelopmental disorders including intellectual disability: a clinical tool kit for mental health professionals. BJPsych Adv. 2022;28(6):350\u20132.","DOI":"10.1192\/bja.2022.65"},{"issue":"supplement 10","key":"9605_CR10","first-page":"32","volume":"66","author":"JT McCracken","year":"2005","unstructured":"McCracken JT. Safety issues with drug therapies for autism spectrum disorders. J Clin Psychiatry. 2005;66(supplement 10):32\u20137.","journal-title":"J Clin Psychiatry"},{"key":"9605_CR11","unstructured":"Sullivan WF, Diepstra H, Heng J, Ally S, Bradley E, Casson I, Witherbee S. Primary care of adults with intellectual and developmental disabilities: 2018 Canadian consensus guidelines. Can Fam Physician. 2018;64:254\u201379."},{"issue":"6","key":"9605_CR12","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2021.1003","volume":"7","author":"S Deb","year":"2021","unstructured":"Deb S, Roy M, Lee R, Majid M, Limbu B, Santambrogio J, et al. Randomised controlled trials of antidepressant and anti-anxiety medications for people with autism spectrum disorder: systematic review and meta-analysis. BJPsych Open. 2021;7(6): e179.","journal-title":"BJPsych Open"},{"issue":"6","key":"9605_CR13","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/jir.12285","volume":"60","author":"M Osugo","year":"2016","unstructured":"Osugo M, Cooper S-A. Interventions for adults with mild intellectual disabilities and mental ill-health: a systematic review. J Intellect Disabil Res. 2016;60(6):615\u201322.","journal-title":"J Intellect Disabil Res"},{"issue":"11","key":"9605_CR14","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1038\/s41436-019-0554-6","volume":"21","author":"S Srivastava","year":"2019","unstructured":"Srivastava S, Love-Nichols JA, Dies KA, Ledbetter DH, Martin CL, Chung WK, et al. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet Med. 2019;21(11):2413\u201321.","journal-title":"Genet Med"},{"issue":"11","key":"9605_CR15","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1038\/s41436-021-01242-6","volume":"23","author":"K Manickam","year":"2021","unstructured":"Manickam K, McClain MR, Demmer LA, Biswas S, Kearney HM, Malinowski J, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23(11):2029\u201337.","journal-title":"Genet Med"},{"issue":"1","key":"9605_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1176\/appi.ajp.2020.20111608","volume":"178","author":"DS Manoli","year":"2021","unstructured":"Manoli DS, State MW. Autism spectrum disorder genetics and the search for pathological mechanisms. Am J Psychiatry. 2021;178(1):30\u20138.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"9605_CR17","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41576-020-0231-2","volume":"21","author":"CP Schaaf","year":"2020","unstructured":"Schaaf CP, Betancur C, Yuen RKC, Parr JR, Skuse DH, Gallagher L, et al. A framework for an evidence-based gene list relevant to autism spectrum disorder. Nat Rev Genet. 2020;21(6):367\u201376.","journal-title":"Nat Rev Genet"},{"key":"9605_CR18","doi-asserted-by":"crossref","unstructured":"Haque B, Khan T, Ushcatz I, Curtis M, Pan A, Wu W, Orkin J, Costain G. Contemporary aetiologies of medical complexity in children: a cohort study. Arch Dis Child. 2023;108(2):147\u20139.","DOI":"10.1136\/archdischild-2022-325094"},{"key":"9605_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107939","volume":"230","author":"D Baribeau","year":"2022","unstructured":"Baribeau D, Anagnostou E. Novel treatments for autism spectrum disorder based on genomics and systems biology. Pharmacol Ther. 2022;230: 107939.","journal-title":"Pharmacol Ther"},{"issue":"8","key":"9605_CR20","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/aur.2999","volume":"16","author":"DA Baribeau","year":"2023","unstructured":"Baribeau DA, Arneja J, Wang X, Howe J, McLaughlin JR, Tu K, et al. Linkage of whole genome sequencing and administrative health data in autism: A proof of concept study. Autism Res. 2023;16(8):1600\u20138.","journal-title":"Autism Res"},{"issue":"1","key":"9605_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13229-021-00465-3","volume":"12","author":"B Mahjani","year":"2021","unstructured":"Mahjani B, De Rubeis S, Gustavsson Mahjani C, Mulhern M, Xu X, Klei L, et al. Prevalence and phenotypic impact of rare potentially damaging variants in autism spectrum disorder. Mol Autism. 2021;12(1):65.","journal-title":"Mol Autism"},{"issue":"3","key":"9605_CR22","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.cell.2019.12.036","volume":"180","author":"FK Satterstrom","year":"2020","unstructured":"Satterstrom FK, Kosmicki JA, Wang J, Breen MS, De Rubeis S, An JY, et al. Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. Cell. 2020;180(3):568-84.e23.","journal-title":"Cell"},{"issue":"9","key":"9605_CR23","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S2215-0366(22)00207-3","volume":"9","author":"J Wolstencroft","year":"2022","unstructured":"Wolstencroft J, Wicks F, Srinivasan R, Wynn S, Ford T, Baker K, et al. Neuropsychiatric risk in children with intellectual disability of genetic origin: IMAGINE, a UK national cohort study. Lancet Psychiatry. 2022;9(9):715\u201324.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"9605_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41525-024-00408-w","volume":"9","author":"A AlMail","year":"2024","unstructured":"AlMail A, Jamjoom A, Pan A, Feng MY, Chau V, D\u2019Gama AM, et al. Consensus reporting guidelines to address gaps in descriptions of ultra-rare genetic conditions. NPJ Genom Med. 2024;9(1):27.","journal-title":"NPJ Genom Med"},{"issue":"9","key":"9605_CR25","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/mp.2015.76","volume":"20","author":"JG Mulle","year":"2015","unstructured":"Mulle JG. The 3q29 deletion confers> 40-fold increase in risk for schizophrenia. Mol Psychiatry. 2015;20(9):1028\u20139.","journal-title":"Mol Psychiatry"},{"issue":"6","key":"9605_CR26","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1176\/appi.ajp.2013.13070864","volume":"171","author":"M Schneider","year":"2014","unstructured":"Schneider M, Debbane M, Bassett AS, Chow EW, Fung WL, van den Bree M, et al. Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. Am J Psychiatry. 2014;171(6):627\u201339.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"9605_CR27","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1176\/appi.ajp.2009.09071016","volume":"167","author":"AS Bassett","year":"2010","unstructured":"Bassett AS, Scherer SW, Brzustowicz LM. Copy number variations in schizophrenia: critical review and new perspectives on concepts of genetics and disease. Am J Psychiatry. 2010;167(8):899\u2013914.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"9605_CR28","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nrg.2017.4","volume":"18","author":"JAS Vorstman","year":"2017","unstructured":"Vorstman JAS, Parr JR, Moreno-De-Luca D, Anney RJL, Nurnberger JI Jr, Hallmayer JF. Autism genetics: opportunities and challenges for clinical translation. Nat Rev Genet. 2017;18(6):362\u201376.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"9605_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13023-024-03026-y","volume":"19","author":"LCS Aman","year":"2024","unstructured":"Aman LCS, Lester SD, Holland AJ, Fletcher PC. Psychotic illness in people with Prader-Willi syndrome: a systematic review of clinical presentation, course and phenomenology. Orphanet J Rare Dis. 2024;19(1):69.","journal-title":"Orphanet J Rare Dis"},{"key":"9605_CR30","doi-asserted-by":"publisher","first-page":"829116","DOI":"10.3389\/fneur.2022.829116","volume":"13","author":"V Zimmern","year":"2022","unstructured":"Zimmern V, Minassian B, Korff C. A review of targeted therapies for monogenic epilepsy syndromes. Front Neurol. 2022;13:829116.","journal-title":"Front Neurol"},{"issue":"9","key":"9605_CR31","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41588-022-01064-5","volume":"54","author":"D Antaki","year":"2022","unstructured":"Antaki D, Guevara J, Maihofer AX, Klein M, Gujral M, Grove J, et al. A phenotypic spectrum of autism is attributable to the combined effects of rare variants, polygenic risk and sex. Nat Genet. 2022;54(9):1284\u201392.","journal-title":"Nat Genet"},{"issue":"3","key":"9605_CR32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrn.2016.183","volume":"18","author":"P Monteiro","year":"2017","unstructured":"Monteiro P, Feng G. SHANK proteins: roles at the synapse and in autism spectrum disorder. Nat Rev Neurosci. 2017;18(3):147.","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"9605_CR33","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41583-020-00418-4","volume":"22","author":"MH Meisler","year":"2021","unstructured":"Meisler MH, Hill SF, Yu W. Sodium channelopathies in neurodevelopmental disorders. Nat Rev Neurosci. 2021;22(3):152\u201366.","journal-title":"Nat Rev Neurosci"},{"issue":"R2","key":"9605_CR34","doi-asserted-by":"publisher","first-page":"R254","DOI":"10.1093\/hmg\/ddz174","volume":"28","author":"JA Fahrner","year":"2019","unstructured":"Fahrner JA, Bjornsson HT. Mendelian disorders of the epigenetic machinery: postnatal malleability and therapeutic prospects. Hum Mol Genet. 2019;28(R2):R254\u201364.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"9605_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.gim.2021.08.007","volume":"24","author":"J Kerkhof","year":"2022","unstructured":"Kerkhof J, Squeo GM, McConkey H, Levy MA, Piemontese MR, Castori M, et al. DNA methylation episignature testing improves molecular diagnosis of Mendelian chromatinopathies. Genet Med. 2022;24(1):51\u201360.","journal-title":"Genet Med"},{"issue":"8","key":"9605_CR36","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/s41588-023-01451-6","volume":"55","author":"AM Valencia","year":"2023","unstructured":"Valencia AM, Sankar A, van der Sluijs PJ, Satterstrom FK, Fu J, Talkowski ME, et al. Landscape of mSWI\/SNF chromatin remodeling complex perturbations in neurodevelopmental disorders. Nat Genet. 2023;55(8):1400\u201312.","journal-title":"Nat Genet"},{"key":"9605_CR37","doi-asserted-by":"crossref","unstructured":"Harris JR, Gao CW, Britton JF, Applegate CD, Bjornsson HT, Fahrner JA. Five years of experience in the epigenetics and chromatin Clinic: what have we learned and where do we go from here?. Hum Genet. 2024;143(4):607\u201324.","DOI":"10.1007\/s00439-023-02537-1"},{"key":"9605_CR38","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1146\/annurev-genom-090613-094245","volume":"15","author":"JA Fahrner","year":"2014","unstructured":"Fahrner JA, Bjornsson HT. Mendelian disorders of the epigenetic machinery: tipping the balance of chromatin states. Annu Rev Genomics Hum Genet. 2014;15:269\u201393.","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"6","key":"9605_CR39","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1192\/bjp.bp.114.151837","volume":"206","author":"NJ Butcher","year":"2015","unstructured":"Butcher NJ, Fung WL, Fitzpatrick L, Guna A, Andrade DM, Lang AE, et al. Response to clozapine in a clinically identifiable subtype of schizophrenia. Br J Psychiatry. 2015;206(6):484\u201391.","journal-title":"Br J Psychiatry"},{"issue":"4","key":"9605_CR40","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/WNF.0000000000000226","volume":"40","author":"K Vermeulen","year":"2017","unstructured":"Vermeulen K, Staal WG, Janzing JG, van Bokhoven H, Egger JI, Kleefstra T. Sleep disturbance as a precursor of severe regression in Kleefstra syndrome suggests a need for firm and rapid pharmacological treatment. Clin Neuropharmacol. 2017;40(4):185\u20138.","journal-title":"Clin Neuropharmacol"},{"issue":"8","key":"9605_CR41","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1002\/ajmg.a.63312","volume":"191","author":"S Srivastava","year":"2023","unstructured":"Srivastava S, Sahin M, Buxbaum JD, Berry-Kravis E, Soorya LV, Thurm A, et al. Updated consensus guidelines on the management of Phelan\u2013McDermid syndrome. Am J Med Genet A. 2023;191(8):2015\u201344.","journal-title":"Am J Med Genet A"},{"key":"9605_CR42","doi-asserted-by":"crossref","unstructured":"van der Sluijs PJ, Pour KS, Berends CL, Kruizinga MD, M\u00fcller AR, van Eeghen AM, Rodr\u00edguez-Girondo M, Juachon MJ, Steenbeek D, Cohen AF, Zuiker RG. Clonazepam repurposing in ARID1B patients through conventional RCT and N-of-1 trials: an experimental strategy for orphan disease development. J Med Genet. 2025;62(3):210\u20138.","DOI":"10.1136\/jmg-2024-109951"},{"issue":"1","key":"9605_CR43","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13023-024-03141-w","volume":"19","author":"L Gizzo","year":"2024","unstructured":"Gizzo L, Bliss G, Palaty C, Kolevzon A. Caregiver perspectives on patient-focused drug development for Phelan-McDermid syndrome. Orphanet J Rare Dis. 2024;19(1):134.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"9605_CR44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13148-015-0112-2","volume":"7","author":"A Sharma","year":"2015","unstructured":"Sharma A, Jamil MA, Nuesgen N, Schreiner F, Priebe L, Hoffmann P, et al. DNA methylation signature in peripheral blood reveals distinct characteristics of human X chromosome numerical aberrations. Clin Epigenetics. 2015;7(1):76.","journal-title":"Clinical Epigenetics"},{"issue":"5","key":"9605_CR45","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41431-019-0554-7","volume":"28","author":"E Tabolacci","year":"2020","unstructured":"Tabolacci E, Pomponi MG, Remondini L, Pietrobono R, Nobile V, Pennacchio G, et al. Methylated premutation of the FMR1 gene in three sisters: correlating CGG expansion and epigenetic inactivation. Eur J Hum Genet. 2020;28(5):567\u201375.","journal-title":"Eur J Hum Genet"},{"key":"9605_CR46","doi-asserted-by":"crossref","unstructured":"Kerns CM, Winder-Patel B, Iosif AM, Nordahl CW, Heath B, Solomon M, et al. Clinically significant anxiety in children with autism spectrum disorder and varied intellectual functioning. J Clin Child Adolesc Psychol. 2020:1\u201316.","DOI":"10.1080\/15374416.2019.1703712"},{"issue":"1","key":"9605_CR47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s11689-024-09552-x","volume":"16","author":"J Summers","year":"2024","unstructured":"Summers J, Baribeau D, Perlman P, Hoang N, Cui S, Krakowski A, et al. An integrated clinical approach to children at genetic risk for neurodevelopmental and psychiatric conditions: interdisciplinary collaboration and research infrastructure. J Neurodev Disord. 2024;16(1):37.","journal-title":"J Neurodev Disord"},{"issue":"5","key":"9605_CR48","doi-asserted-by":"publisher","first-page":"e63472","DOI":"10.1002\/ajmg.a.63472","volume":"194","author":"A Bouman","year":"2024","unstructured":"Bouman A, Geelen JM, Kummeling J, Schenck A, van der Zwan YG, Klein WM, et al. Growth, body composition, and endocrine-metabolic profiles of individuals with Kleefstra syndrome provide directions for clinical management and translational studies. Am J Med Genet A. 2024;194(5): e63472.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"9605_CR49","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41392-023-01333-7","volume":"8","author":"Y-L Wu","year":"2023","unstructured":"Wu Y-L, Lin Z-J, Li C-C, Lin X, Shan S-K, Guo B, et al. Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study. Signal Transduct Target Ther. 2023;8(1):98.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"9605_CR50","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13347","volume":"35","author":"M Fonseca","year":"2023","unstructured":"Fonseca M, Carmo F, Martel F. Metabolic effects of atypical antipsychotics: Molecular targets. J Neuroendocrinol. 2023;35(12): e13347.","journal-title":"J Neuroendocrinol"}],"container-title":["Journal of Neurodevelopmental Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-025-09605-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11689-025-09605-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-025-09605-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T13:06:52Z","timestamp":1745500012000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneurodevdisorders.biomedcentral.com\/articles\/10.1186\/s11689-025-09605-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9605"],"URL":"https:\/\/doi.org\/10.1186\/s11689-025-09605-9","relation":{},"ISSN":["1866-1955"],"issn-type":[{"value":"1866-1955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research Ethics Board at Holland Bloorview Kids Rehabilitation Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"DB is the site lead for a clinical\u00a0trial funded by MapLight Therapeutics. The remaining authors declare no potential competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}